Increasing the use of Next Generation Sequencing (NGS) in oncology requires further cost reduction and technology acceleration. 8 health procurers from 5 countries (BE, FR, DE, ES, IT) invite potentially interested bidders to submit an offer for their oncNGS pre-commercial procurement.
Aim of the procurement is to develop an affordable integrated solution for predictive, prognostic and diagnostic analysis in liquid biopsies of solid tumours based on NGS technology. Deadline for submission of offers: extended to 17 October 2022.